Correlation Between Entero Therapeutics, and Moleculin Biotech

Can any of the company-specific risk be diversified away by investing in both Entero Therapeutics, and Moleculin Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Entero Therapeutics, and Moleculin Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Entero Therapeutics, and Moleculin Biotech, you can compare the effects of market volatilities on Entero Therapeutics, and Moleculin Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Entero Therapeutics, with a short position of Moleculin Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Entero Therapeutics, and Moleculin Biotech.

Diversification Opportunities for Entero Therapeutics, and Moleculin Biotech

-0.32

Correlation Coefficient

Entero Therapeutics,  Moleculin Biotech

Very good diversification

The 3 months correlation between Entero and Moleculin is -0.32. Overlapping area represents the amount of risk that can be diversified away by holding Entero Therapeutics, and Moleculin Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Moleculin Biotech and Entero Therapeutics, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Entero Therapeutics, are associated (or correlated) with Moleculin Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Moleculin Biotech has no effect on the direction of Entero Therapeutics, i.e., Entero Therapeutics, and Moleculin Biotech go up and down completely randomly.

Pair Corralation between Entero Therapeutics, and Moleculin Biotech

Given the investment horizon of 90 days Entero Therapeutics, is expected to generate 1.54 times more return on investment than Moleculin Biotech. However, Entero Therapeutics, is 1.54 times more volatile than Moleculin Biotech. It trades about 0.12 of its potential returns per unit of risk. Moleculin Biotech is currently generating about -0.07 per unit of risk. If you would invest  42.00  in Entero Therapeutics, on October 9, 2024 and sell it today you would earn a total of  24.00  from holding Entero Therapeutics, or generate 57.14% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	98.39%
Values	Daily Returns

Entero Therapeutics,  vs.  Moleculin Biotech

Entero Therapeutics,

Risk-Adjusted Performance

9 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Entero Therapeutics, are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Entero Therapeutics, displayed solid returns over the last few months and may actually be approaching a breakup point.

Moleculin Biotech

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Moleculin Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Pair Trading with Entero Therapeutics, and Moleculin Biotech

The main advantage of trading using opposite Entero Therapeutics, and Moleculin Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Entero Therapeutics, position performs unexpectedly, Moleculin Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Moleculin Biotech will offset losses from the drop in Moleculin Biotech's long position.

The idea behind Entero Therapeutics, and Moleculin Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.